Abaxis (NASDAQ:ABAX) will be issuing its quarterly earnings data after the market closes on Wednesday, January 24th. Analysts expect the company to announce earnings of $0.26 per share for the quarter.

Abaxis (NASDAQ:ABAX) last released its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The company had revenue of $58.90 million for the quarter, compared to the consensus estimate of $60.85 million. Abaxis had a net margin of 11.98% and a return on equity of 10.18%. Abaxis’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 earnings per share. On average, analysts expect Abaxis to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of Abaxis (NASDAQ:ABAX) opened at $62.21 on Wednesday. The stock has a market cap of $1,417.20, a price-to-earnings ratio of 51.84 and a beta of 0.86. Abaxis has a 12 month low of $43.66 and a 12 month high of $63.18.

Abaxis announced that its Board of Directors has authorized a stock buyback plan on Tuesday, October 24th that permits the company to repurchase $21.00 million in outstanding shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Several brokerages have recently weighed in on ABAX. Zacks Investment Research downgraded shares of Abaxis from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. BidaskClub downgraded shares of Abaxis from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Northcoast Research raised shares of Abaxis from a “neutral” rating to a “buy” rating in a research note on Friday, January 5th. Bank of America reduced their target price on shares of Abaxis from $42.00 to $39.00 and set an “underperform” rating on the stock in a research note on Wednesday, October 25th. Finally, UBS Group raised shares of Abaxis from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $49.63.

TRADEMARK VIOLATION WARNING: “Abaxis (ABAX) Set to Announce Quarterly Earnings on Wednesday” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/17/abaxis-abax-set-to-announce-quarterly-earnings-on-wednesday.html.

Abaxis Company Profile

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Earnings History for Abaxis (NASDAQ:ABAX)

Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.